Cargando…

Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. The proportion of infected individuals who seroconvert is still an open question. In addition, it has been shown in some individuals that viral genome can be detected up to 3 months after symptom r...

Descripción completa

Detalles Bibliográficos
Autores principales: Wajnberg, Ania, Mansour, Mayce, Leven, Emily, Bouvier, Nicole M, Patel, Gopi, Firpo-Betancourt, Adolfo, Mendu, Rao, Jhang, Jeffrey, Arinsburg, Suzanne, Gitman, Melissa, Houldsworth, Jane, Sordillo, Emilia, Paniz-Mondolfi, Alberto, Baine, Ian, Simon, Viviana, Aberg, Judith, Krammer, Florian, Reich, David, Cordon-Cardo, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518831/
https://www.ncbi.nlm.nih.gov/pubmed/33015652
http://dx.doi.org/10.1016/S2666-5247(20)30120-8
_version_ 1783587460577492992
author Wajnberg, Ania
Mansour, Mayce
Leven, Emily
Bouvier, Nicole M
Patel, Gopi
Firpo-Betancourt, Adolfo
Mendu, Rao
Jhang, Jeffrey
Arinsburg, Suzanne
Gitman, Melissa
Houldsworth, Jane
Sordillo, Emilia
Paniz-Mondolfi, Alberto
Baine, Ian
Simon, Viviana
Aberg, Judith
Krammer, Florian
Reich, David
Cordon-Cardo, Carlos
author_facet Wajnberg, Ania
Mansour, Mayce
Leven, Emily
Bouvier, Nicole M
Patel, Gopi
Firpo-Betancourt, Adolfo
Mendu, Rao
Jhang, Jeffrey
Arinsburg, Suzanne
Gitman, Melissa
Houldsworth, Jane
Sordillo, Emilia
Paniz-Mondolfi, Alberto
Baine, Ian
Simon, Viviana
Aberg, Judith
Krammer, Florian
Reich, David
Cordon-Cardo, Carlos
author_sort Wajnberg, Ania
collection PubMed
description BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. The proportion of infected individuals who seroconvert is still an open question. In addition, it has been shown in some individuals that viral genome can be detected up to 3 months after symptom resolution. We investigated both seroconversion and PCR positivity in a large cohort of convalescent serum donors in the New York City (NY, USA) region. METHODS: In this observational study, we ran an outreach programme in the New York City area. We recruited participants via the REDCap (Vanderbilt University, Nashville, TN, USA) online survey response. Individuals with confirmed or suspected SARS-CoV-2 infection were screened via PCR for presence of viral genome and via ELISA for presence of anti-SARS-CoV-2 spike antibodies. One-way ANOVA and Fisher's exact test were used to measure the association of age, gender, symptom duration, and days from symptom onset and resolution with positive antibody results. FINDINGS: Between March 26 and April 10, 2020, we measured SARS-CoV-2 antibody titres in 1343 people. Of the 624 participants with confirmed SARS-CoV-2 infection who had serologies done after 4 weeks, all but three seroconverted to the SARS-CoV-2 spike protein, whereas 269 (37%) of 719 participants with suspected SARS-CoV-2 infection seroconverted. PCR positivity was detected up to 28 days from symptom resolution. INTERPRETATION: Most patients with confirmed COVID-19 seroconvert, potentially providing immunity to reinfection. We also report that in a large proportion of individuals, viral genome can be detected via PCR in the upper respiratory tract for weeks after symptom resolution, but it is unclear whether this signal represents infectious virus. Analysis of our large cohort suggests that most patients with mild COVID-19 seroconvert 4 weeks after illness, and raises questions about the use of PCR to clear positive individuals. FUNDING: None.
format Online
Article
Text
id pubmed-7518831
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-75188312020-09-28 Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study Wajnberg, Ania Mansour, Mayce Leven, Emily Bouvier, Nicole M Patel, Gopi Firpo-Betancourt, Adolfo Mendu, Rao Jhang, Jeffrey Arinsburg, Suzanne Gitman, Melissa Houldsworth, Jane Sordillo, Emilia Paniz-Mondolfi, Alberto Baine, Ian Simon, Viviana Aberg, Judith Krammer, Florian Reich, David Cordon-Cardo, Carlos Lancet Microbe Articles BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. The proportion of infected individuals who seroconvert is still an open question. In addition, it has been shown in some individuals that viral genome can be detected up to 3 months after symptom resolution. We investigated both seroconversion and PCR positivity in a large cohort of convalescent serum donors in the New York City (NY, USA) region. METHODS: In this observational study, we ran an outreach programme in the New York City area. We recruited participants via the REDCap (Vanderbilt University, Nashville, TN, USA) online survey response. Individuals with confirmed or suspected SARS-CoV-2 infection were screened via PCR for presence of viral genome and via ELISA for presence of anti-SARS-CoV-2 spike antibodies. One-way ANOVA and Fisher's exact test were used to measure the association of age, gender, symptom duration, and days from symptom onset and resolution with positive antibody results. FINDINGS: Between March 26 and April 10, 2020, we measured SARS-CoV-2 antibody titres in 1343 people. Of the 624 participants with confirmed SARS-CoV-2 infection who had serologies done after 4 weeks, all but three seroconverted to the SARS-CoV-2 spike protein, whereas 269 (37%) of 719 participants with suspected SARS-CoV-2 infection seroconverted. PCR positivity was detected up to 28 days from symptom resolution. INTERPRETATION: Most patients with confirmed COVID-19 seroconvert, potentially providing immunity to reinfection. We also report that in a large proportion of individuals, viral genome can be detected via PCR in the upper respiratory tract for weeks after symptom resolution, but it is unclear whether this signal represents infectious virus. Analysis of our large cohort suggests that most patients with mild COVID-19 seroconvert 4 weeks after illness, and raises questions about the use of PCR to clear positive individuals. FUNDING: None. The Author(s). Published by Elsevier Ltd. 2020-11 2020-09-25 /pmc/articles/PMC7518831/ /pubmed/33015652 http://dx.doi.org/10.1016/S2666-5247(20)30120-8 Text en © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Articles
Wajnberg, Ania
Mansour, Mayce
Leven, Emily
Bouvier, Nicole M
Patel, Gopi
Firpo-Betancourt, Adolfo
Mendu, Rao
Jhang, Jeffrey
Arinsburg, Suzanne
Gitman, Melissa
Houldsworth, Jane
Sordillo, Emilia
Paniz-Mondolfi, Alberto
Baine, Ian
Simon, Viviana
Aberg, Judith
Krammer, Florian
Reich, David
Cordon-Cardo, Carlos
Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study
title Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study
title_full Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study
title_fullStr Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study
title_full_unstemmed Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study
title_short Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study
title_sort humoral response and pcr positivity in patients with covid-19 in the new york city region, usa: an observational study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518831/
https://www.ncbi.nlm.nih.gov/pubmed/33015652
http://dx.doi.org/10.1016/S2666-5247(20)30120-8
work_keys_str_mv AT wajnbergania humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT mansourmayce humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT levenemily humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT bouviernicolem humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT patelgopi humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT firpobetancourtadolfo humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT mendurao humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT jhangjeffrey humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT arinsburgsuzanne humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT gitmanmelissa humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT houldsworthjane humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT sordilloemilia humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT panizmondolfialberto humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT baineian humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT simonviviana humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT abergjudith humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT krammerflorian humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT reichdavid humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy
AT cordoncardocarlos humoralresponseandpcrpositivityinpatientswithcovid19inthenewyorkcityregionusaanobservationalstudy